Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation.
Phase:
PHASE2
Details
Lead Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Collaborators:
Apices Soluciones S.L. GERCOR - Multidisciplinary Oncology Cooperative Group